BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BC Week In Review | Mar 17, 2014
Clinical News

ACH-3102: Additional Phase IIa data

Additional data from 8 treatment-naïve patients with HCV genotype 1b infection carrying the CC genotype of the interleukin-28B (IL-28B; IFNL3 ) gene in an open-label Phase IIa trial showed that oral ACH-3102 plus ribavirin for 12...
BC Week In Review | Dec 9, 2013
Clinical News

BIT225: Interim Phase II data

Interim data from 12 treatment-naïve patients co-infected with HIV and chronic HCV genotype 1 or 3 infection in an open-label, Thai Phase II trial showed that all 6 patients with HCV genotype 3 infection who...
BC Week In Review | Aug 19, 2013
Company News

Biosurfit S.A., Epistem, Qlucore AB, French National Institute of Health and Medical Research (INSERM), Inserm Transfert Initiative diagnostics news

Epistem said it received a three-year €1.5 million ($2 million) award from the EU's Framework Programme 7 (FP7) as part of a €6 million ($8 million) award for the PoC-HCV consortium project to develop point-of-care...
BC Week In Review | Jun 17, 2013
Clinical News

Deleobuvir: Additional Phase IIb data

Additional data from the open-label, international Phase IIb SOUND-C3 trial showed that 19 of 20 (95%) evaluable treatment-naïve patients with chronic HCV genotype 1b infection who received once-daily faldaprevir (BI 201335) plus twice-daily deleobuvir (BI...
BC Week In Review | Jun 17, 2013
Clinical News

Faldaprevir: Additional Phase IIb data

Additional data from the open-label, international Phase IIb SOUND-C3 trial showed that 19 of 20 (95%) evaluable treatment-naïve patients with chronic HCV genotype 1b infection who received once-daily faldaprevir (BI 201335) plus twice-daily deleobuvir (BI...
BC Week In Review | May 6, 2013
Clinical News

Simeprevir: Additional Phase III data

Medivir reported subgroup data from the double-blind, placebo-controlled, international Phase III QUEST-2 trial in 391 treatment-naive patients with HCV genotype 1 infection evaluating once-daily 150 mg oral simeprevir for 12 weeks plus Pegasys peginterferon alfa-2a...
BC Week In Review | May 6, 2013
Clinical News

Simeprevir: Additional Phase III data

Medivir reported subgroup data from the double-blind, placebo-controlled, international Phase III QUEST-1 trial in 394 treatment-naive patients with HCV genotype 1 infection evaluating once-daily 150 mg oral simeprevir for 12 weeks plus Pegasys peginterferon alfa-2a...
BC Week In Review | Apr 29, 2013
Clinical News

ACH-3102: Additional Phase IIa data

Data from all 8 treatment-naïve patients with HCV genotype 1b infection carrying the CC genotype of the interleukin-28B (IL-28B; IFNL3 ) gene in an open-label Phase IIa trial showed that oral ACH-3102 plus ribavirin for 12...
BC Week In Review | Apr 29, 2013
Clinical News

Incivek telaprevir: Interim Phase IIIb data

Interim data from 85 evaluable patients in the 12-week treatment arm of the open-label, placebo-controlled, international Phase IIIb CONCISE trial showed that twice-daily 1,125 mg Incivek plus peginterferon and ribavirin for 12 weeks led to...
Items per page:
1 - 10 of 40